Molindone - Supernus Pharmaceuticals

Drug Profile

Molindone - Supernus Pharmaceuticals

Alternative Names: Molindone hydrochloride; Molindone XR; SPN 810; SPN-810M; Zalvari

Latest Information Update: 24 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antipsychotics; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder

Most Recent Events

  • 21 Aug 2018 Supernus Pharmaceuticals plans a phase II trial for Attention-deficit hyperactivity disorder (In children) in USA (NCT03638466)
  • 31 Jul 2018 Phase-III clinical trials in Attention-deficit hyperactivity disorder (Adjunctive treatment, In adolescents) in USA (PO) (NCT03597503)
  • 27 Feb 2018 Supernus Pharmaceuticals plans the phase III trial in Attention-deficit hyperactivity disorder (In adolescents) by July 2018 (NCT03597503)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top